Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
NASDAQ:PSTV
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$0.16 - $2.31
Previous CloseN/A
Volume69.06K
Average Volume (3M)10.37M
Market Cap
$53.03M
Enterprise Value$4.20M
Total Cash (Recent Filing)$13.29M
Total Debt (Recent Filing)$21.00K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Apr 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding178,371,230
10 Day Avg. Volume5,342,237
30 Day Avg. Volume10,365,055
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.85
Price to Sales (P/S)1.31
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.08
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit0.90
Enterprise Value/Ebitda-0.26
Forecast
1Y Price Target
$1.50Price Target Upside158.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$7.03M
Bulls Say, Bears Say
Bulls Say
Payer Coverage And Market AccessLicensing to provide CNSide testing across most U.S. states combined with national coverage agreements with major insurers positions the test to scale volume and drive broader physician adoption through improved reimbursement.
Regulatory And Clinical PathwayFDA feedback indicating that an accelerated approval pathway could be appropriate for the leptomeningeal metastases program, alongside progressing enrollment in glioblastoma studies, supports the potential for an expedited regulatory strategy and future registration discussions.
Reimbursement And BillingAssignment of a dedicated medical billing code for Reyobiq should reduce billing friction and simplify reimbursement, enabling faster integration into healthcare billing systems and smoother clinical use once approved.
Bears Say
Clinical And Commercial Execution RiskReliance on successful trial outcomes and payer adoption exposes the company to material downside if clinical setbacks occur or commercial uptake is slower than anticipated.
Financing And Dilution RiskRecent public equity financings increase share dilution risk and may place downward pressure on existing shareholders' positions as capital is raised to support development.
Valuation And Analyst OutlookAnalyst lowered the price target to reflect elevated development and commercialization risks, signaling constrained near-term upside until key milestones are achieved.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $53.03M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Apr 16, 2026 which is in 40 days.
How were Plus Therapeutics’s earnings last quarter?
Currently, no data Available
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 178,371,230 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.50 (158.62% Upside)
$1.50 (158.62% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
167.56%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Stock 12 Month Forecast
Average Price Target
$1.50
▲(158.62% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
0.38% Insiders
1.00% Mutual Funds
1.31% Other Institutional Investors
96.46% Public Companies and Individual Investors
Options Prices
Currently, No data available
---